Free Trial
NASDAQ:GTBP

GT Biopharma (GTBP) Stock Price, News & Analysis

GT Biopharma logo
$2.11 -0.03 (-1.59%)
As of 11:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About GT Biopharma Stock (NASDAQ:GTBP)

Key Stats

Today's Range
$2.07
$2.14
50-Day Range
$2.05
$3.80
52-Week Range
$1.72
$4.10
Volume
48,693 shs
Average Volume
248,579 shs
Market Capitalization
$6.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Strong Buy

Company Overview

GT Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

GTBP MarketRank™: 

GT Biopharma scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GT Biopharma has received no research coverage in the past 90 days.

  • Read more about GT Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GT Biopharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GT Biopharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about GT Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    11.48% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in GT Biopharma has recently increased by 40.25%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GT Biopharma does not currently pay a dividend.

  • Dividend Growth

    GT Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.48% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in GT Biopharma has recently increased by 40.25%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    GT Biopharma has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for GT Biopharma this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    3 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GT Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.40% of the stock of GT Biopharma is held by insiders.

  • Percentage Held by Institutions

    Only 8.15% of the stock of GT Biopharma is held by institutions.

  • Read more about GT Biopharma's insider trading history.
Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Stock News Headlines

GT Biopharma, Inc. (GTBP) - Yahoo Finance
GTBP GT Biopharma, Inc. - Seeking Alpha
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Stocks in play: GT Biopharma, Inc.
See More Headlines

GTBP Stock Analysis - Frequently Asked Questions

GT Biopharma's stock was trading at $3.05 at the beginning of 2025. Since then, GTBP stock has decreased by 31.6% and is now trading at $2.0850.

GT Biopharma, Inc. (NASDAQ:GTBP) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12.

Shares of GT Biopharma reverse split on the morning of Monday, February 5th 2024.The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

Last Earnings
5/15/2025
Today
7/15/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GTBP
Previous Symbol
OTCMKTS:OXISD
CIK
109657
Fax
N/A
Employees
8
Year Founded
1965

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+414.0%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,033.08%
Return on Assets
-223.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.73
Quick Ratio
0.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.75) per share
Price / Book
-2.85

Miscellaneous

Outstanding Shares
3,270,000
Free Float
3,162,000
Market Cap
$7.00 million
Optionable
No Data
Beta
1.48

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:GTBP) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners